STK11 and neoplasm: Recent evidence showed that the concomitance of G12C and STK11 mutations increase the sensitivity to anti-KRAS G12C therapies, such as sotorasib or adagrasib [29], and decreases the sensitivity to immunotherapeutic agents [30], confirming the importance of a multigenic tumor characterization before any treatment decision making.